M
Marcelle Van Mechelen
Researcher at GlaxoSmithKline
Publications - 32
Citations - 3425
Marcelle Van Mechelen is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Adjuvant & Antigen. The author has an hindex of 17, co-authored 31 publications receiving 3067 citations.
Papers
More filters
Journal ArticleDOI
AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
Arnaud Didierlaurent,Sandra Morel,Laurence Lockman,Sandra L. Giannini,Michel Bisteau,Harald Carlsen,Anders Kielland,Olivier Vosters,Nathalie Vanderheyde,Francesca Schiavetti,Daniel Larocque,Marcelle Van Mechelen,Nathalie Garçon +12 more
TL;DR: Results support a model in which the addition of MPL to aluminum salt enhances the vaccine response by rapidly triggering a local cytokine response leading to an optimal activation of APCs, and support the favorable safety profile of AS04 adjuvanted vaccines.
Journal ArticleDOI
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
Sandra L. Giannini,Emmanuel Hanon,Philippe Moris,Marcelle Van Mechelen,Sandra Morel,Francis Dessy,Marc Fourneau,Brigitte Desiree Alberte Colau,JoAnn Suzich,Genevieve Losonksy,Marie-Therese Martin,Gary Dubin,Martine Wettendorff +12 more
TL;DR: The role of the AS04 adjuvant, which includes the immunostimulant MPL, in triggering a persistent vaccine-induced immune response of high quality is strongly supported.
Journal ArticleDOI
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
TL;DR: The promising clinical results strongly support the concept of Adjuvant Systems and allow for further development of new vaccines, best adapted to the target population and the immune mechanisms of protection.
Journal ArticleDOI
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.
Sandra Morel,Arnaud Didierlaurent,Patricia Bourguignon,Sophie Delhaye,Benoît Baras,Valérie Jacob,Camille Planty,Abdelatif Elouahabi,Pol Harvengt,Harald Carlsen,Anders Kielland,Chomez Patrick,Nathalie Garçon,Marcelle Van Mechelen +13 more
TL;DR: AS03's promotion of monocytes as the principal antigen-presenting cells, and its effects on granulocytes and cytokines, may all contribute to enhancing the antigen-specific adaptive immune response.
Journal ArticleDOI
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
TL;DR: The licensing of two AS04-adjuvanted vaccines and the initiation of Phase III trials with an AS01-adJuvanted vaccine demonstrate the potential to develop new or improved human vaccines that contain MPL or MPL and QS-21.